Sugi Predict

Sugi Predict / Compounds / SCHEMBL6625328

SCHEMBL6625328

SCHEMBL6625328

NNc1ccc2[nH]cnc2c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 3/20 0.47
▸ KDM4E B2RXH2 2/20 0.47
▸ ALDH1A1 P00352 1/20 0.47
▸ APEX1 P27695 1/20 0.47
▸ RECQL P46063 1/20 0.47
▸ BLM P54132 1/20 0.47
▸ TDP1 Q9NUW8 1/20 0.47
▸ PRKCI P41743 1/20 0.44
▸ RAD52 P43351 1/20 0.43
▸ ADRA2A P08913 1/20 0.42
▸ ADRA2C P18825 1/20 0.42
▸ ADRA1D P25100 1/20 0.42
▸ ADRA1A P35348 1/20 0.42
▸ ADRA1B P35368 1/20 0.42
▸ QPCT Q16769 6/20 0.40
▸ CDK1 P06493 2/20 0.39
▸ POLB P06746 1/20 0.37
▸ HTT P42858 1/20 0.37
▸ SMN1; SMN2 Q16637 1/20 0.37
▸ MMP12 P39900 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6625320 0.85 ADRA2A (0.58) MAPTKDM4EALDH1A1APEX1RECQL
SCHEMBL2541307 0.81 EGFR (0.43) MAPTKDM4EALDH1A1APEX1RECQL
SCHEMBL21646358 0.81 ADRA2A (0.42) MAPTKDM4EALDH1A1APEX1RECQL
SCHEMBL31036089 0.81 EGFR (0.43) MAPTKDM4EALDH1A1APEX1RECQL
SCHEMBL19558168 0.77 ADRA2A (0.40) MAPTKDM4EALDH1A1APEX1RECQL
SCHEMBL2544215 0.77 CDK2 (0.46) MAPTKDM4EALDH1A1TDP1ADRA2A
SCHEMBL18789600 0.77 ADRA2A (0.40) MAPTKDM4EALDH1A1APEX1RECQL
SCHEMBL19558167 0.77 ADRA2A (0.40) MAPTKDM4EALDH1A1APEX1RECQL
SCHEMBL18126690 0.77 MMP12 (0.41) MAPTKDM4EALDH1A1APEX1RECQL
SCHEMBL6886180 0.75 XDH (0.36) MAPTKDM4EALDH1A1APEX1RECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250186433-A1 ACSS2 INHIBITORS AND METHODS OF USE THEREOF EPIVARIO, INC. 2025-06-12 — — US disclosed
US-12133852-B2 ACSS2 inhibitors and methods of use thereof EPIVARIO, INC. (US) 2024-11-05 — — US disclosed
US-20220305010-A1 ACSS2 INHIBITORS AND METHODS OF USE THEREOF METABOMED LTD. (IL) 2022-09-29 — — US disclosed
CN-114008025-A ACSS2 inhibitors and methods of use thereof 美特波米德有限公司 2022-02-01 — — CN disclosed
EP-2471786-B1 AMINOPYRAZOLE DERIVATIVE CHUGAI PHARMACEUTICAL CO LTD (JP) 2015-11-04 — — EP disclosed
US-9102692-B2 Aminopyrazole derivative CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2015-08-11 — — US disclosed
US-20140315856-A1 AMINOPYRAZOLE DERIVATIVE F. HOFFMANN-LA ROCHE AG (CH) 2014-10-23 — — US disclosed
US-8829199-B2 Aminopyrazole derivative CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2014-09-09 — — US disclosed
CN-102574836-B Aminopyrazole Derivatives CHUGAI PHARMACEUTICAL CO LTD 2014-04-16 — — CN disclosed
US-20120208811-A1 Aminopyrazole Derivative F. HOFFMANN-LA ROCHE AG (CH) 2012-08-16 — — US disclosed
CN-102574836-A Aminopyrazole Derivatives CHUGAI PHARMACEUTICAL CO LTD 2012-07-11 — — CN disclosed
EP-2471786-A1 AMINOPYRAZOLE DERIVATIVE Chugai Seiyaku Kabushiki Kaisha (JP) 2012-07-04 — — EP disclosed
EP-1060181-B1 SUBSTITUTED PYRROLOBENZIMIDAZOLES FOR TREATING INFLAMMATORY DISEASES ORTHO MCNEIL PHARM INC (US) 2004-05-06 — — EP disclosed
US-6469174-B1 COMPOUNDS OF THE INVENTION INHIBIT THE PRODUCTION OF THE INFLAMMATORY CYTOKINES TNF- ALPHA AND IL- 1 BETA , THE OVERPRODUCTION OF WHICH ARE CHARACTERISTIC OF INFLAMMATORY DISEASES ORTHO-MCNEIL PHARMACEUTICAL, INC. 2002-10-22 — — US disclosed
EP-1060181-A1 SUBSTITUTED PYRROLOBENZIMIDAZOLES FOR TREATING INFLAMMATORY DISEASES Ortho-Mcneil Pharmaceutical, Inc. (US) 2000-12-20 — — EP disclosed
US-6147096-A COMPOUNDS OF THE INVENTION INHIBIT THE PRODUCTION OF CYTOKINES, PARTICULARLY TNF-.ALPHA. AND IL-1, WHICH MEDIATE INFLAMMATORY RESPONSES ORTHO MCNEIL PHARMACEUTICAL, INC. (US) 2000-11-14 — — US disclosed
WO-1999043680-A1 SUBSTITUTED PYRROLOBENZIMIDAZOLES FOR TREATING INFLAMMATORY DISEASES ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) 1999-09-02 — — WO disclosed
US-3936444-A FROM A LACTIM-ETHER AND AN ARYL OR HETEROARYL HYDRAZINE, ACID CATALYST BAYER AKTIENGESELLSCHAFT (DT) 1976-02-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250186433-A1 ACSS2 INHIBITORS AND METHODS OF USE THEREOF ACSS2, GLS2, ADSS2 MAPT 2884/4885KDM4E 2609/4885ALDH1A1 238/4885
US-20120208811-A1 Aminopyrazole Derivative FGFR1, FGFR3, FGFR4 MAPT 4214/4885KDM4E 1500/4885ALDH1A1 919/4885
US-20140315856-A1 AMINOPYRAZOLE DERIVATIVE H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, IL4I1, CYP3A43 MAPT 4330/4885KDM4E 2063/4885ALDH1A1 873/4885
US-20220305010-A1 ACSS2 INHIBITORS AND METHODS OF USE THEREOF ACSS2, GLS2, ADSS2 MAPT 2884/4885KDM4E 2609/4885ALDH1A1 238/4885
US-12133852-B2 ACSS2 inhibitors and methods of use thereof ACSS2, GLS2, ADSS2 MAPT 2884/4885KDM4E 2609/4885ALDH1A1 238/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.